Tylenol autism lawsuits revived by appeals court
Analysis based on 7 articles · First reported Jul 13, 2026 · Last updated Jul 15, 2026
The ruling revives litigation risk for Kenvue and retailers, potentially increasing legal costs and reputational exposure. However, the court did not rule on causation, limiting immediate financial impact.
The U.S. Court of Appeals for the Second Circuit reversed a district court's dismissal of over 500 lawsuits against Kenvue and major retailers, alleging that prenatal use of Tylenol (acetaminophen) causes autism and ADHD in children. The appeals court ruled that expert testimony from Andrea Baccarelli and others should not have been excluded, as it followed accepted scientific methodologies. The decision does not establish causation but allows cases to proceed to trial. The scientific evidence remains disputed, with some studies suggesting a link and others finding none. Kenvue maintains the safety of its product.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard